首页> 中文期刊>中国医药导报 >塞来昔布对不同激素受体乳腺癌细胞的放疗增敏作用的初步研究

塞来昔布对不同激素受体乳腺癌细胞的放疗增敏作用的初步研究

     

摘要

Objective To discuss the radiation sensitizing effect of selective cyclooxygenase-2 (COX-2) inhibitor, Celecoxib in breast cancer cells with different estrogen receptors status. Methods Two cell lines, MCF-7 and MDA-MB-231 in logarithmic phase were divided into four groups: control group, drug group, radiation group and experimental group (radiation plus Celecoxib). The cell activity was examined by CCK-8 test. The invastion ability of the cells was analyzed by Transwell test. And the radiation sensitizing effect was detected by clone formation experiment. Results Celecoxib could inhibit the activity of both cell lines and in a dose dependent manner. Celecoxib alone could inhibit the invasion ability of both cell lines as well. Guinness formula showed, after pretreated by 20 μmol/L Celecoxib for 24 hours, both cell lines showed maximum radiation sensitizing effect at 2 Gy dose point. Conclusion Celecoxib can increase the radiation sensitivity of MCF-7 and MDA-MB-231, and inhibit the invasion ability of both cell lines as well. The mechanism should be further investigated.%目的 对选择性环氧化酶-2(COX-2)抑制剂塞来昔布对不同激素受体乳腺癌细胞的放疗增敏作用进行初步探讨.方法 取指数生长期的不同激素受体乳腺癌细胞MCF-7和MDA-MB-231,分为对照组、药物组、照射组和实验组(射线+塞来昔布),利用CCK-8实验测定细胞活性,Transwell实验观察细胞侵袭能力变化,细胞克隆形成实验检测放射增敏作用.结果 在一定浓度范围内,塞来昔布可抑制两种细胞的活性,且抑制效应呈量效关系,塞来昔布还能抑制细胞侵袭能力.塞来昔布与X射线联用可显著降低两种细胞的存活分数,在2 Gy照射时最为显著.结论 塞来昔布对人乳腺癌细胞MCF-7和MDA-MB-231有显著的放射增敏作用,且能抑制两种细胞的侵袭能力,其机制有待进一步研究.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号